A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
NCT ID: NCT02706951
Last Updated: 2024-01-30
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
648 participants
INTERVENTIONAL
2016-03-23
2022-08-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study objective of Period 2 is to evaluate the long term safety, tolerability, and efficacy of upadacitinib 30 mg QD and 15 mg QD in adults with RA who had completed Period 1.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
NCT02706873
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
NCT02629159
A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone
NCT02066389
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
NCT03086343
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT04909801
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants who met eligibility criteria were to be randomized in a 2:2:1:1 ratio to one of four treatment groups:
* Group 1: upadacitinib 30 mg QD (Period 1) → upadacitinib 30 mg QD (Period 2)
* Group 2: upadacitinib 15 mg QD (Period 1) → upadacitinib 15 mg QD (Period 2)
* Group 3: MTX (Period 1) → upadacitinib 30 mg QD (Period 2)
* Group 4: MTX (Period 1) → upadacitinib 15 mg QD (Period 2)
Starting with implementation of Protocol Amendment 5, all participants in the extension period will receive open-label upadacitinib 15 mg QD, including those currently on upadacitinib 30 mg QD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Upadacitinib 30 mg
Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks.
Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260.
Upadacitinib
Tablet; Oral
Placebo Methotrexate
Capsule; Oral
Upadacitinib 15 mg
Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks.
Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260.
Upadacitinib
Tablet; Oral
Placebo Methotrexate
Capsule; Oral
Methotrexate / Upadacitinib 30 mg
Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks.
Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260.
Methotrexate
Capsule; Oral
Upadacitinib
Tablet; Oral
Placebo Upadacitinib
Tablet; Oral
Placebo Methotrexate
Capsule; Oral
Methotrexate / Upadacitinib 15 mg
Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks.
Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260.
Methotrexate
Capsule; Oral
Upadacitinib
Tablet; Oral
Placebo Upadacitinib
Tablet; Oral
Placebo Methotrexate
Capsule; Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methotrexate
Capsule; Oral
Upadacitinib
Tablet; Oral
Placebo Upadacitinib
Tablet; Oral
Placebo Methotrexate
Capsule; Oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must have been on oral or parenteral MTX therapy \>= 3 months and on a stable dose for \>= 4 weeks prior to first dose of study drug.
* Must have discontinued all conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) (other than MTX) \>= 4 weeks prior to first dose of study drug.
* Meets the following minimum disease activity criteria: \>= 6 swollen joints (based on 66 joint counts) and \>= 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
Exclusion Criteria
* Prior exposure to any biological disease-modifying anti-rheumatic drugs (bDMARDs).
* Current diagnosis of inflammatory joint disease other than RA. Current diagnosis of secondary Sjogren's Syndrome is permitted.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AbbVie Inc.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rheum Assoc of North Alabama /ID# 146009
Huntsville, Alabama, United States
Alabama Medical Group, PC /ID# 153941
Mobile, Alabama, United States
ArthroCare Arthritis Care & Re /ID# 143751
Gilbert, Arizona, United States
Elite Clinical Studies, LLC /ID# 143760
Phoenix, Arizona, United States
University of Arizona Cancer Center - North Campus /ID# 147175
Tucson, Arizona, United States
NEA Baptist Womens Clinic /ID# 148904
Jonesboro, Arkansas, United States
C.V. Mehta MD, Med Corporation /ID# 143762
Hemet, California, United States
Arthritis Assoc & Osteo Ctr /ID# 147176
Colorado Springs, Colorado, United States
Ctr Rheum, Immuno, Arthritis /ID# 143766
Fort Lauderdale, Florida, United States
South Florida Research Ph I-IV /ID# 151983
Miami Springs, Florida, United States
Advent Clinical Research /ID# 143767
Pinellas Park, Florida, United States
Sarasota Arthritis Center /ID# 146011
Sarasota, Florida, United States
W. Broward Rheum Assoc Inc. /ID# 146010
Tamarac, Florida, United States
Clinical Research West FL /ID# 148726
Tampa, Florida, United States
SW FL Clin Res Ctr, Tampa, FL /ID# 143763
Tampa, Florida, United States
University of South Florida /ID# 146004
Tampa, Florida, United States
BayCare Medical Group, Inc. /ID# 151985
Tampa, Florida, United States
BayCare Medical Group, Inc. /ID# 163595
Tampa, Florida, United States
Jefrey D. Lieberman, MD, P.C. /ID# 151816
Decatur, Georgia, United States
Great Lakes Clinical Trials /ID# 150935
Chicago, Illinois, United States
PRN Professional Research Network of Kansas, LLC /ID# 143761
Wichita, Kansas, United States
Ochsner Clinic Foundation /ID# 153573
Baton Rouge, Louisiana, United States
The Arthritis & Diabetes Clinic, Inc. /ID# 160809
Monroe, Louisiana, United States
Vanguard Medical Research, LLC /ID# 153124
Shreveport, Louisiana, United States
Mansfield Health Center /ID# 161627
Mansfield, Massachusetts, United States
Quality Clinical Research Inc. /ID# 156415
Omaha, Nebraska, United States
Dartmouth-Hitchcock Medical Center /ID# 146008
Lebanon, New Hampshire, United States
Albuquerque Clinical Trials, Inc /ID# 147618
Albuquerque, New Mexico, United States
Arthritis and Osteo Assoc /ID# 147177
Las Cruces, New Mexico, United States
Coastal Carolina Health Care /ID# 149275
New Bern, North Carolina, United States
STAT Research, Inc. /ID# 143770
Vandalia, Ohio, United States
Health Research Oklahoma /ID# 159550
Oklahoma City, Oklahoma, United States
Healthcare Research Consultant /ID# 147632
Tulsa, Oklahoma, United States
Innovative Clinical Research /ID# 143757
Greenville, South Carolina, United States
Nashville Arthritis and Rheumatology /ID# 162641
Nashville, Tennessee, United States
Tekton Research, Inc. /ID# 159554
Austin, Texas, United States
Diagnostic Group Integrated He /ID# 148725
Beaumont, Texas, United States
Trinity Universal Res Assoc /ID# 150138
Carrollton, Texas, United States
Arth and Osteo Clin Brazo Valley /ID# 160810
College Station, Texas, United States
Adriana Pop-Moody MD Clinic PA /ID# 147627
Corpus Christi, Texas, United States
Accurate Clinical Management /ID# 143768
Houston, Texas, United States
Accurate Clinical Research /ID# 143769
Houston, Texas, United States
Pioneer Research Solutions, Inc. /ID# 143765
Houston, Texas, United States
P&I Clinical Research /ID# 151358
Lufkin, Texas, United States
SW Rheumatology Res. LLC /ID# 147620
Mesquite, Texas, United States
Sun Research Institute /ID# 159553
San Antonio, Texas, United States
Arthritis Clinic of Central TX /ID# 149266
San Marcos, Texas, United States
Adv Rheumatology of Houston /ID# 162609
The Woodlands, Texas, United States
DM Clinical Research /ID# 151359
Tomball, Texas, United States
Arthritis & Osteoporosis Clinic /ID# 143752
Waco, Texas, United States
Ctr for Arth and Rheum Disease /ID# 143759
Chesapeake, Virginia, United States
Aurora Rheumatology and Immunotherapy Center /ID# 160811
Franklin, Wisconsin, United States
Mautalen Salud e Investigacion /ID# 145980
Buenos Aires, , Argentina
Ctr Privado Med Familiar /ID# 149183
Buenos Aires, , Argentina
Consultorio Reumatologic Pampa /ID# 145979
Buenos Aires, , Argentina
Centro de Educación Médica e Investigaciones Clínicas "Norberto Quimo" - CEMIC /ID# 149176
Buenos Aires, , Argentina
Cordis S.A. /Id# 152621
Salta, , Argentina
Centro de Enfermedades /ID# 153543
Santa Fe, , Argentina
Royal Prince Alfred Hospital /ID# 146028
Camperdown, New South Wales, Australia
Rheuma-Zentrum Wien-Oberlaa /ID# 144728
Vienna, , Austria
Algemeen Stedelijk Ziekenhuis /ID# 148720
Aalst, Oost-Vlaanderen, Belgium
ReumaClinic Genk /ID# 146030
Genk, , Belgium
Diag Consult Ctr 17 Sofia EOOD /ID# 144730
Sofia, , Bulgaria
UMHAT Sv. Ivan Rilski /ID# 147351
Sofia, , Bulgaria
Reg. Clinical Hosptial Concepcion /ID# 151267
Concepción, , Chile
Quantum Research LTDA. /ID# 145984
Puerto Varas, , Chile
Quantum Research Stgo. /ID# 145983
Santiago, , Chile
CTCenter MaVe, s.r.o. /ID# 144823
Olomouc, Olomoucký kraj, Czechia
Nuselská poliklinika, Revmatologie /ID# 145986
Prague, Praha 4, Czechia
Thomayerova nemocnice /ID# 144736
Prague, Praha 4, Czechia
RHEUMA s.r.o. /ID# 144737
Břeclav, , Czechia
Medical Plus, s.r.o. /ID# 144821
Uherské Hradište, , Czechia
MediTrials /ID# 159745
Tartu, Tartu, Estonia
North Estonian Medical Centre /ID# 145455
Tallinn, , Estonia
General Hospital of Athens "Ippokratio" /ID# 144739
Athens, , Greece
Vital Medical Center Orvosi es /ID# 144740
Veszprém, Veszprém megye, Hungary
Magyar Honvedseg Egeszsegugyi Kozpont /ID# 144743
Budapest, , Hungary
Pest Megyei Flor Ferenc Korhaz /ID# 144742
Kistarcsa, , Hungary
Fejer Megyei Szent Gyorgy Korh /ID# 144741
Székesfehérvár, , Hungary
Barzilai Medical Center /ID# 144744
Ashkelon, , Israel
Bnai Zion Medical Center /ID# 144745
Haifa, , Israel
The Lady Davis Carmel MC /ID# 147174
Haifa, , Israel
Sheba Medical Center /ID# 144824
Ramat Gan, , Israel
Universita di Catanzaro Magna Graecia /ID# 144747
Catanzaro, Calabria, Italy
A.O.U.I. di Verona Policlinico /ID# 144746
Verona, , Italy
Kondo Clinic for Rheum & Ortho /ID# 148268
Fukuoka, Fukuoka, Japan
NHO Kyushu Medical Center /ID# 148279
Fukuoka, Fukuoka, Japan
NHO Kyushu Medical Center /ID# 148280
Fukuoka, Fukuoka, Japan
Aso Iizuka Hospital /ID# 148272
Iizuka-shi, Fukuoka, Japan
Inoue Hospital /ID# 148069
Takasaki, Gunma, Japan
Bay Side Misato Medical Center /ID# 148281
Kochi, Kochi, Japan
Center for Arthritis and Clinical Rheumatology Matsubara Clinic /ID# 148269
Kumamoto, Kumamoto, Japan
Kumamoto Shinto General Hospital /ID# 148286
Kumamoto, Kumamoto, Japan
Nagasaki University Hospital /ID# 149859
Nagasaki, Nagasaki, Japan
Sasebo Chuo Hospital /ID# 148275
Sasebo, Nagasaki, Japan
Osaka Red Cross Hospital /ID# 148267
Osaka, Osaka, Japan
Seirei Hamamatsu General Hosp /ID# 148270
Hamamatsu, , Japan
Ohira Orthopaedic Hospital /ID# 157944
Hyūga, , Japan
Shirahama Hamayu Hospital /ID# 148277
Nishimura, , Japan
Sanuki Municipal Hospital /ID# 158080
Sanuki, , Japan
Hokkaido University Hospital /ID# 148285
Sapporo, , Japan
Hokkaido Medical Center for Rheumatic Diseases /ID# 148274
Sapporo, , Japan
Miyasato Clinic /ID# 148271
Shūnan, , Japan
Takaoka Rheumatic Orthopedic Clinic /ID# 148068
Takaoka, , Japan
Matsuta Clinic /ID# 148278
Tokyo, , Japan
National Hospital Organization Shimoshizu National Hospital /ID# 148273
Yotsukaidō, , Japan
Desarrollos Biomedicos y Biotc /ID# 147379
Monterrey, Nuevo León, Mexico
Cryptex Investigación Clínica S.A de C.V /ID# 147095
Mexico City, , Mexico
Medyczne Centrum Hetmanska /ID# 144751
Poznan, Greater Poland Voivodeship, Poland
WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 157622
Wroclaw, Lower Silesian Voivodeship, Poland
REUMED Sp.z o.o. Filia nr 1 /ID# 144752
Lublin, Lublin Voivodeship, Poland
Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 149521
Warsaw, Masovian Voivodeship, Poland
Osteo-Medic spolka cywilna /ID# 144753
Bialystok, Podlaskie Voivodeship, Poland
Centrum Badań Klinicznych Pi-House /ID# 149520
Gdansk, Pomeranian Voivodeship, Poland
NZOZ Centrum Reumatologiczne /ID# 144749
Elblag, Warmian-Masurian Voivodeship, Poland
Instituto Portugues De Reumatologia /ID# 149281
Lisbon, Lisbon District, Portugal
Centro Hospitalar De Vila Nova /ID# 146036
Vila Nova de Gaia, Porto District, Portugal
Centro Hospitalar Lisboa Norte, EPE /ID# 146035
Lisbon, , Portugal
Centro Hospitalar Baixo Vouga /ID# 152916
Porto, , Portugal
Dr. Ramon L. Ortega-Colon, MD /ID# 145989
Carolina, , Puerto Rico
Ponce School of Medicine /ID# 145990
Ponce, , Puerto Rico
Spitalul Municipal Ploiesti /ID# 144756
Ploieşti, , Romania
Clinical Hospital No.1 n.a. N.I.Pirogov /ID# 147255
Moscow, Moscow, Russia
LLC Medical Center /ID# 144758
Novosibirsk, Novosibirsk Oblast, Russia
Perm Clinical Center of FMBA /ID# 145993
Perm, Permskiy Kray, Russia
Tver Regional Clinical Hosp. /ID# 147254
Tver', Tver Oblast, Russia
Сity Clinical Hospital 4 /ID# 145994
Ivanovo, , Russia
City Clinical Hospital Botkina /ID# 145995
Moscow, , Russia
City Clinical Hospital #5 /ID# 149832
Nizhny Novgorod, , Russia
Orenburg State Medical Academy /ID# 145992
Orenburg, , Russia
Republican Clin Hos n.a. Baran /ID# 147251
Petrozavodsk, , Russia
Samara Regional Clinical Hosp /ID# 150934
Samara, , Russia
Reg Clin Hosp n.a. Kuvatova G. /ID# 144757
Ufa, , Russia
Yaroslavi State Medical Univer /ID# 147253
Yaroslavl, , Russia
Institute for Rheumatology /ID# 144759
Belgrade, Beograd, Serbia
Institute for Rheumatology /ID# 144761
Belgrade, Beograd, Serbia
Institute for Rheumatology /ID# 144762
Belgrade, Beograd, Serbia
Special Hospital for Rheuma /ID# 144760
Novi Sad, Vojvodina, Serbia
Wits Clinical Research Site /ID# 149835
Johannesburg, Gauteng, South Africa
University of Pretoria /ID# 148740
Pretoria, Gauteng, South Africa
Synexus Helderberg Clinical Tr /ID# 148724
Cape Town, Western Cape, South Africa
Tiervlei Trial Centre /ID# 153086
Cape Town, Western Cape, South Africa
Hospital Plató /ID# 145999
Barcelona, , Spain
Hospital Univ Germans Trias I /ID# 146037
Barcelona, , Spain
Hospital Infanta Luisa /ID# 144771
Seville, , Spain
Hospital Universitario de Valm /ID# 144770
Seville, , Spain
Hospital Universitario La Fe /ID# 158013
Valencia, , Spain
Uludağ Üniversitesi Atatürk Rehabilitasyon Uygulama ve Araştırma Merkezi /ID# 144772
Osmangazi, Bursa, Turkey (Türkiye)
Lviv Regional Clinical Hospita /ID# 154448
Lviv, Lviv Oblast, Ukraine
Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 146002
Vinnytsia, Vinnytsia Oblast, Ukraine
Regional Clinical Hospital /ID# 152007
Ivano-Frankivsk, , Ukraine
NSC-Strazhesko Ist Cardiology /ID# 152004
Kiev, , Ukraine
Zaporizhzhia Regional Clinical /ID# 146000
Zaporizhia, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu SI, Lippe R, Curtis JR. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Feb;11(1):97-112. doi: 10.1007/s40744-023-00621-6. Epub 2023 Nov 20.
Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392.
Fleischmann R, Curtis JR, Charles-Schoeman C, Mysler E, Yamaoka K, Richez C, Palac H, Dilley D, Liu J, Strengholt S, Burmester G. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023 Sep;82(9):1130-1141. doi: 10.1136/ard-2023-223916. Epub 2023 Jun 12.
Conaghan PG, Pavelka K, Hsieh SC, Bonnington TL, Kent TC, Marchbank K, Edwards CJ. Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials. Rheumatol Adv Pract. 2023 Feb 8;7(1):rkad017. doi: 10.1093/rap/rkad017. eCollection 2023.
Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019 Jun 8;393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2. Epub 2019 May 23.
Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.
Smolen JS, Emery P, Rigby W, Tanaka Y, Vargas JI, Jain M, Kato K, Carter KM, Khan N, Phillips C, Meerwein S, Cohen SB. Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study. RMD Open. 2025 May 11;11(2):e005051. doi: 10.1136/rmdopen-2024-005051.
Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.
Kakehasi AM, Radominski SC, Baravalle MD, Palazuelos FCI, Garcia-Garcia C, Arruda MS, Curi M, Liu J, Qiao M, Velez-Sanchez P, Vargas JI. Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program. Clin Rheumatol. 2023 May;42(5):1249-1258. doi: 10.1007/s10067-023-06513-y. Epub 2023 Jan 30.
Bergman M, Buch MH, Tanaka Y, Citera G, Bahlas S, Wong E, Song Y, Zueger P, Ali M, Strand V. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials. Rheumatol Ther. 2022 Dec;9(6):1517-1529. doi: 10.1007/s40744-022-00483-4. Epub 2022 Sep 20.
Bergman M, Tundia N, Yang M, Orvis E, Clewell J, Bensimon A. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. Adv Ther. 2021 Dec;38(12):5649-5661. doi: 10.1007/s12325-021-01930-4. Epub 2021 Oct 12.
Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27.
Strand V, Tundia N, Wells A, Buch MH, Radominski SC, Camp HS, Friedman A, Suboticki JL, Dunlap K, Goldschmidt D, Bergman M. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatology (Oxford). 2021 Jul 1;60(7):3209-3221. doi: 10.1093/rheumatology/keaa770.
Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021 Mar;80(3):304-311. doi: 10.1136/annrheumdis-2020-218510. Epub 2020 Oct 28.
Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis. Clin Pharmacol Ther. 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671. Epub 2019 Nov 30.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Related Info.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-003376-75
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
M15-555
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.